A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate the Safety and Immunogenicity of the Therion Recombinant Vaccinia-HIV-1 IIIB ENV/GAG/POL Vaccine (TCB-3B) and MN RGP 120/HIV-1 In Alum.

NACompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

Not specified

Study Completion Date

July 31, 1999

Conditions

HIV Infections

Interventions

BIOLOGICAL

MN rgp120/HIV-1

BIOLOGICAL

TBC-3B Vaccine

Trial Locations (4)

Vanderbilt Univ. Hosp. AVEG, Nashville

UW - Seattle AVEG, Seattle

JHU AVEG, Baltimore

St. Louis Univ. School of Medicine AVEG, St Louis

All Listed Sponsors

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH